Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Endocrinology›Condition·Updated Jun 28, 2026·v1

Osteoporosis

Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration, leading to increased fracture risk. Diagnosis is based on DXA T-score ≤ -2.5 or a fragility fracture. Management includes calcium/vitamin D supplementation, weight-bearing exercise, fall prevention, and pharmacotherapy with antiresorptive agents (bisphosphonates, denosumab) or anabolic agents (teriparatide, romosozumab) for high-risk patients. Early treatment reduces fracture risk by up to 70%.

High Evidence95 references·1,786 words·8 min read·v1
osteoporosisbone mineral densityfracture preventionbisphosphonatesdenosumabteriparatideromosozumabFRAXDXApostmenopausal osteoporosisglucocorticoid-induced osteoporosisfragility fracture

Quick Reference

RxDrug of choiceAlendronate 70 mg orally once weekly (first-line antiresorptive) or zoledronic acid 5 mg IV yearly for patients who cannot tolerate oral therapy.
AltAlternativesDenosumab 60 mg SC every 6 months; teriparatide 20 mcg SC daily (anabolic, 24-month limit); romosozumab 210 mg SC monthly (dual-action, 12-month limit); raloxifene 60 mg daily (SERM, for postmenopausal women only).
⊘AvoidBisphosphonates in eGFR <35 mL/min; romosozumab within 1 year of MI or stroke; teriparatide/abaloparatide in Paget disease, prior skeletal radiation, or open epiphyses; raloxifene in patients with history of VTE.
DxTest of choiceDual-energy X-ray absorptiometry (DXA) of lumbar spine and hip; T-score ≤ -2.5 is diagnostic.
ScKey scoreFRAX (Fracture Risk Assessment Tool), 10-year probability of major osteoporotic fracture and hip fracture.
→When to referFragility fracture at any site; very high fracture risk (T-score ≤ -3.0, recent fracture, multiple fractures); suspected secondary cause; failure of first-line therapy; consideration of anabolic agents.
Osteoporosis is a silent disease until fracture occurs; diagnose with DXA T-score ≤ -2.5 or fragility fracture; treat with bisphosphonates or denosumab as first-line, and consider anabolics for very high-risk patients; always ensure calcium/vitamin D, exercise, and fall prevention.
Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration, leading to increased fracture risk. It is defined by a T-score ≤ -2.5 on DXA or by the presence of a fragility fracture. The disease is most common in postmenopausal women and older adults, with hip fractures carrying 20-30% one-year mortality. Management includes lifestyle measures, calcium/vitamin D, and pharmacotherapy with antiresorptive or anabolic agents.

Overview and Recommendations

Background

  • •Osteoporosis is a systemic skeletal disease defined by low bone mass and microarchitectural deterioration of bone tissue, leading to enhanced bone fragility and a consequent increase in fracture risk. It is the most common metabolic bone disease worldwide, affecting an estimated 200 million women and causing over 8.9 million fractures annually, one fracture every 3 seconds.
  • •Postmenopausal osteoporosis (Type I) occurs in women within 15-20 years of due to estrogen-deficiency-driven accelerated bone loss, preferentially affecting trabecular bone (vertebrae, distal forearm). Senile osteoporosis (Type II) affects both sexes after age 70-75 due to age-related decline in bone formation, decreased calcium absorption, and , involving both cortical and trabecular bone.
  • •Secondary osteoporosis results from an identifiable cause such as glucocorticoid therapy (≥5 mg/day equivalent for ≥3 months), aromatase inhibitors, hypogonadism, hyperthyroidism, hyperparathyroidism, malabsorption (celiac disease, inflammatory bowel disease), chronic kidney disease, or immobilization. Up to 30% of men and 50% of premenopausal women with osteoporosis have an underlying secondary cause.
  • •The WHO operational definition uses bone mineral density (BMD) measured by dual-energy X-ray absorptiometry (DXA): T-score ≤ -2.5 defines osteoporosis; T-score between -1.0 and -2.5 defines osteopenia (low bone mass). The -2.5 threshold identifies approximately 30% of postmenopausal women at the hip, correlating with lifetime fracture risk. A clinical diagnosis can also be made in the presence of a fragility fracture regardless of T-score.
  • •Following a , mortality is 20-24% in the first year, and many survivors lose independent mobility. A prior fragility fracture is the single strongest predictor of a subsequent fracture, doubling the risk independent of BMD. The disease is underdiagnosed, especially in men and special populations such as adults with cerebral palsy.

Evaluation

  • •Suspect osteoporosis in any patient aged ≥50 with a low-trauma (fragility) fracture, one resulting from a fall from standing height or less, or from routine activities such as bending or coughing. Classic fracture sites are the hip (proximal femur), vertebral body (spine), and distal forearm (wrist); also consider fractures of the humerus, pelvis, ribs, and tibia as osteoporotic.
  • •Ask about prior fragility fractures, parental history of hip fracture, current smoking, alcohol intake (≥3 units/day), glucocorticoid use (≥5 mg prednisolone daily for ≥3 months), and secondary causes such as rheumatoid arthritis, type 1 diabetes, hyperthyroidism, hypogonadism, chronic liver disease, and malabsorption. In women, document menopausal status and age at menopause.
  • •Examine for height loss (measure against prior records), kyphosis (dowager's hump), rib-to-pelvis distance ≤2 fingerbreadths on lateral inspection, and signs of vertebral compression (acute back pain with band-like radiation, worsened by weight-bearing, relieved by lying flat). Two-thirds of vertebral fractures are clinically silent.
  • •Order central dual-energy X-ray absorptiometry (DXA) of the lumbar spine and hip as the gold-standard diagnostic test. The femoral neck and total hip are standard sites for diagnosis and monitoring; the forearm (33% radius) is used when spine or hip cannot be measured or in hyperparathyroidism. Peripheral DXA or quantitative ultrasound (QUS) of the heel can be used for initial risk stratification but are not diagnostic.
  • •Diagnostic criteria: T-score ≤ -2.5 at the lumbar spine, total hip, or femoral neck defines osteoporosis. A T-score between -1.0 and -2.5 indicates osteopenia. In patients with a fragility fracture and T-score > -2.5, a clinical diagnosis of osteoporosis can still be made based on fracture history.
  • •Calculate the 10-year fracture probability using the FRAX tool (Fracture Risk Assessment Tool) in patients with osteopenia or those aged 40-90 with risk factors. FRAX integrates 12 clinical risk factors with or without femoral neck BMD. Most guidelines recommend pharmacotherapy when the 10-year major osteoporotic fracture probability exceeds 20% or the hip fracture probability exceeds 3%.
  • •Also consider alternative imaging: quantitative computed tomography (QCT) for volumetric BMD, high-resolution peripheral QCT (HR-pQCT) for microarchitecture assessment, and artificial intelligence (AI) algorithms that derive BMD from routine radiographs (opportunistic screening). These are not first-line but useful when DXA is unavailable.
  • •Evaluate for secondary causes in all patients with osteoporosis, especially if BMD is unexpectedly low or declines rapidly. Initial laboratory evaluation includes serum calcium, phosphate, alkaline phosphatase, creatinine, 25-hydroxyvitamin D, intact PTH, thyroid-stimulating hormone (TSH), testosterone (in men), 24-hour urinary calcium, celiac serology, and serum protein electrophoresis (if vertebral fractures or anemia suggest ).
  • •In patients with suspected primary hyperparathyroidism, include forearm DXA because up to 20% have osteoporosis isolated to the distal radius. Forearm DXA is also recommended in hyperparathyroidism to detect cortical bone loss.
  • •Assess fall risk as part of the evaluation: ask about falls in the past year, review medications that increase fall risk (sedatives, antihypertensives, anticholinergics), and perform a simple balance test (e.g., timed up-and-go). Multifactorial fall prevention programs reduce fall rates by 25-30%.

Management

  • •Ensure adequate calcium and vitamin D intake: total daily calcium (diet plus supplement) 1000-1200 mg; vitamin D 800-1000 IU/day for adults aged ≥50. Supplement only in patients with low dietary intake; exceeding 1200 mg/day calcium provides no additional benefit and may increase risk of nephrolithiasis and cardiovascular events.
  • •Prescribe weight-bearing aerobic exercise (30-45 minutes, 4-5 days/week) and resistance training (2-3 days/week) to improve BMD, muscle strength, and balance. Walking ≥30 min/day is associated with a 20% lower hazard of incident osteoporosis. Balance training (tai chi, yoga) reduces fall risk.
  • •Implement multifactorial fall prevention: medication review (deprescribe sedatives, antihypertensives), home safety assessment (remove loose rugs, improve lighting, install grab bars), vision correction, and appropriate footwear.
  • •Initiate pharmacotherapy in patients with T-score ≤ -2.5, or prior hip or vertebral fracture, or T-score between -1.0 and -2.5 with FRAX 10-year major fracture risk ≥20% or hip fracture risk ≥3%. First-line antiresorptive therapy: alendronate 70 mg orally once weekly, risedronate 35 mg orally once weekly (or 150 mg monthly), or zoledronic acid 5 mg intravenously once yearly.
  • •Alternative antiresorptive: denosumab 60 mg subcutaneously every 6 months. Denosumab is preferred in patients with renal impairment (eGFR <35 mL/min) where bisphosphonates are contraindicated. Monitor serum calcium before each dose; correct hypocalcemia and ensure adequate vitamin D. Do not stop denosumab without transitioning to a bisphosphonate to prevent rebound vertebral fractures.
  • •For patients at very high fracture risk (T-score ≤ -3.0, recent fragility fracture, multiple fractures, or FRAX major fracture probability >20%), consider first-line anabolic or dual-action therapy: teriparatide 20 mcg subcutaneously daily (lifetime limit 24 months), abaloparatide 80 mcg subcutaneously daily (24-month limit), or romosozumab 210 mg subcutaneously monthly (12-month limit).
  • •Romosozumab is contraindicated in patients with a history of myocardial infarction or stroke within the preceding year due to increased risk of major adverse cardiovascular events (MACE). Teriparatide and abaloparatide are contraindicated in Paget disease, prior radiation to the skeleton, or open epiphyses due to osteosarcoma risk.
  • •After completing an anabolic or dual-action course (12-24 months), transition immediately to a potent antiresorptive (denosumab or zoledronic acid) to preserve gained bone. The optimal transition window is within one month of the last dose.
  • •Monitor BMD by DXA every 1-2 years after initiating therapy until stable, then every 2 years. Use bone turnover markers (P1NP for formation, CTX-1 for resorption) at 3-6 months to confirm adherence and response: a decrease in CTX-1 ≥30% (antiresorptive) or increase in P1NP ≥30% (anabolic) correlates with subsequent BMD improvement.
  • •For bisphosphonates, reassess fracture risk after 3-5 years. In low-risk patients (T-score > -2.5, no fractures), consider a drug holiday of 2-3 years. High-risk patients may continue for up to 10 years. During a drug holiday, monitor BMD every 2 years; resume therapy if BMD drops by more than the least significant change or if a fragility fracture occurs.
  • •Denosumab should not be interrupted without bridging to an antiresorptive. If therapy is stopped, initiate a bisphosphonate at the time of the next missed dose to prevent rebound vertebral fractures.
  • •Avoid non-dihydropyridine calcium channel blockers (diltiazem, verapamil) in patients with heart failure, but this is not specific to osteoporosis. In osteoporosis, avoid combining PTH analogs with romosozumab (no trial support, theoretical additive risk). Avoid exceeding the 24-month lifetime limit for PTH analogs.
  • •Refer to an endocrinologist or rheumatologist for patients with unexplained osteoporosis (especially men, premenopausal women, or those with multiple fractures despite therapy), suspected secondary causes requiring further workup, or when considering anabolic therapy. Refer to a fracture liaison service if available for coordinated post-fracture care.
  • •Discharge criteria for hospitalized patients with fragility fracture: ensure initiation of bone-protective therapy (if indicated), calcium/vitamin D supplementation, fall prevention education, and follow-up with primary care or specialist within 4-6 weeks for DXA and treatment plan.

Board Review — High Yield

  • •Fragility fracture, A fracture from a fall from standing height or less; the strongest predictor of future fracture, doubling risk independent of BMD.
  • •T-score ≤ -2.5, WHO diagnostic threshold for osteoporosis; identifies ~30% of postmenopausal women at the hip.
  • •FRAX, 10-year fracture probability tool integrating 12 clinical risk factors ± femoral neck BMD; treatment threshold typically ≥20% major fracture or ≥3% hip fracture.
  • •Bisphosphonates, First-line antiresorptive; alendronate 70 mg weekly, risedronate 35 mg weekly, zoledronic acid 5 mg yearly; drug holiday after 3-5 years in low-risk patients.
  • •Denosumab, RANKL inhibitor 60 mg SC every 6 months; superior BMD gains but requires uninterrupted therapy; rebound fractures if stopped without bridging to bisphosphonate.
  • •Anabolic agents, Teriparatide (PTH analog) 20 mcg SC daily, abaloparatide 80 mcg SC daily, romosozumab (sclerostin inhibitor) 210 mg SC monthly; reserved for very high fracture risk; lifetime limit 24 months for PTH analogs, 12 months for romosozumab.
  • •Romosozumab contraindication, History of MI or stroke within 1 year due to MACE risk (FDA black-box warning).
  • •Secondary osteoporosis, Up to 30% of men and 50% of premenopausal women have an identifiable cause; common causes: glucocorticoids, aromatase inhibitors, hypogonadism, hyperparathyroidism, malabsorption.
  • •Calcium and vitamin D, Total calcium intake 1000-1200 mg/day; vitamin D 800-1000 IU/day; supplementation only beneficial in those with low dietary intake or deficiency.
  • •Fall prevention, Multifactorial programs reduce falls by 25-30%; include medication review, home safety, vision correction, balance training.

Deep Dive — Evidence Details

References

  1. [1]

    Ryan JM, Burke J, Byrne R et al.. “Musculoskeletal health among adults with cerebral palsy: A systematic review.” Developmental medicine and child neurology (2026). PMID: 42281159 ↗

    L1SR_OBSCited in: Definition and Classification, Epidemiology and Risk Factors, Monitoring and Treatment Duration
  2. [2]

    Lu C, Zhang L, Xue C et al.. “Comparative efficacy and safety of odanacatib, abaloparatide, denosumab, teriparatide, and bisphosphonates for male osteoporosis: a systematic review and network meta-analysis.” Frontiers in endocrinology (2026). PMID: 42181204 ↗

    L1SR_OBSCited in: Definition and Classification, Pharmacologic Therapy – Antiresorptive Agents, Pharmacologic Therapy – Anabolic and Dual-Action Agents, Special Populations (Glucocorticoid-Induced, Male, Postmenopausal, Pediatric)
  3. [3]

    da Rocha-Loures MAA, de Freitas Zerbini CA, de Azevedo E et al.. “Management of osteoporosis in older men: a systematic review of randomized trials of pharmacological and non-pharmacological strategies.” Archives of osteoporosis (2026). PMID: 42174334 ↗

    L1SR_OBSCited in: Definition and Classification, Differential Diagnosis and Evaluation for Secondary Causes
  4. [4]

    Frassineti I, Cinci L, Magnini A et al.. “Cone Beam Computed Tomography of Bonejaws in Patients With Primary Osteoporosis: A Systematic Review.” Current osteoporosis reports (2026). PMID: 42166070 ↗

    L1SR_OBSCited in: Definition and Classification
  5. [5]

    Law LS, Siddiqui F, Al-Aamri A et al.. “The effect of pulse steroid therapy on bone density and turnover: A systematic review and meta-analysis.” Annals of the Academy of Medicine, Singapore (2026). PMID: 42142321 ↗

    L1SR_OBSCited in: Definition and Classification, Differential Diagnosis and Evaluation for Secondary Causes
  6. [6]

    Spiegl UJA, Schanderl P, Zimmermann V et al.. “Prospective clinical feasibility assessment of the Osteoporotic Pelvis Fracture Score (OFP-Score)-a multicenter prospective cohort study.” BMC geriatrics (2026). PMID: 42177405 ↗

    L2COHORTCited in: Definition and Classification
  7. [7]

    Xu N, Liu P, Liu C et al.. “Efficacy of denosumab versus zoledronate on preventing secondary osteoporotic vertebral compression fracture: a prospective study with 2-year follow-up.” Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2026). PMID: 42159645 ↗

    L1COHORTCited in: Definition and Classification, Pharmacologic Therapy – Antiresorptive Agents
  8. [8]

    Martiniakova M, Sarocka A, Penzes N et al.. “Linking the relationship between drug-induced osteoporosis and the gut microbiota.” Frontiers in endocrinology (2026). PMID: 42305264 ↗

    L5REVIEW_NARRATIVECited in: Definition and Classification, Differential Diagnosis and Evaluation for Secondary Causes
  9. [9]

    Kim SH, Choi E, Cha Y et al.. “Bone mineral density testing rates and fracture risk across cancers with different mortality risks: a nationwide matched cohort study.” Archives of osteoporosis (2026). PMID: 42343050 ↗

    L2COHORTCited in: Epidemiology and Risk Factors, Diagnosis and Bone Mineral Density Measurement, Prognosis and Outcomes
  10. [10]

    Gottlieb J, Wald A, Bucher B et al.. “Follow-Up Care After Adult Lung Transplantation: Summary of an Evidence-Based Clinical Practice Guideline for German-Speaking Countries.” Respiration; international review of thoracic diseases (2026). PMID: 42301957 ↗

    L1GUIDELINECited in: Epidemiology and Risk Factors, Monitoring and Treatment Duration, Guidelines and Resources
  11. [11]

    Madihian M, Ranjbar K, Maffulli N. “Investigating the Effect of Blood Groups on the Risk of Musculoskeletal Injuries: A Systematic Review.” Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine (2026). PMID: 42348571 ↗

    L1SR_OBSCited in: Epidemiology and Risk Factors
  12. [12]

    Babaee E, Soheyli M, Nafissi N. “Long-Term Side Effects of Breast Cancer Treatments: A Systematic Review.” The breast journal (2026). PMID: 42345555 ↗

    L1SR_OBSCited in: Epidemiology and Risk Factors, Non-Pharmacologic Management (Lifestyle, Nutrition, Fall Prevention), Prognosis and Outcomes
  13. [13]

    Sørensen MER, Lindhardt Petersen SS, Overgaard AL et al.. “The impact of interleukin-6 receptor inhibitors on risk of diabetes mellitus in patients with giant cell arteritis: a cohort study.” Rheumatology international (2026). PMID: 42362950 ↗

    L2COHORTCited in: Epidemiology and Risk Factors
  14. [14]

    Pietro J, Kaadan A, Cotton T et al.. “Effects of Normocalcemic Hyperparathyroidism on Structural Bone Compromise: A Prospective Observational Cohort Study.” Journal of bone metabolism (2026). PMID: 42316446 ↗

    L2COHORTCited in: Epidemiology and Risk Factors
  15. [15]

    Jiang Y, Zeng Y, Xin L et al.. “Eldecalcitol and calcium supplementation in Chinese women with postmenopausal osteoporosis: a prospective observational cohort study.” Journal of bone and mineral metabolism (2026). PMID: 42303801 ↗

    L2COHORTCited in: Epidemiology and Risk Factors, Special Populations (Glucocorticoid-Induced, Male, Postmenopausal, Pediatric)
  16. [16]

    Devaraja V, Rajoo S, Valayatham VM et al.. “Retrospective Study of Clinical Characteristics, Natural History and Predictive Factors for Mild Autonomous Cortisol Secretion (MACS) in Patients with Adrenal Incidentalomas in Malaysia.” Journal of the ASEAN Federation of Endocrine Societies (2026). PMID: 42311546 ↗

    L3COHORTCited in: Epidemiology and Risk Factors
  17. [17]

    Haro M, Muñoz-San Martín M, Gárate G et al.. “Impaired bone status in high frequency episodic or chronic migraine women: A case-control study with blood and densitometric parameters.” Cephalalgia : an international journal of headache (2026). PMID: 42340335 ↗

    L3CASE_CONTROLCited in: Epidemiology and Risk Factors
  18. [18]

    Dong B, Tang R, Wan D et al.. “Unveiling the efficacy predictors and potential mechanisms of Semen Cuscutae against osteoporosis via machine learning and meta-analysis: a preclinical study.” Frontiers in immunology (2026). PMID: 42358988 ↗

    L1SR_OBSCited in: Pathophysiology, Diagnosis and Bone Mineral Density Measurement, Pharmacologic Therapy – Antiresorptive Agents, Monitoring and Treatment Duration
  19. [19]

    Kindaro D, Chiu J, Hariharan M et al.. “The impact of parathyroid hormone supplementation on dental implant osseointegration in osteoporotic subjects: A systematic review.” Journal of oral biosciences (2026). PMID: 42218012 ↗

    L1SR_OBSCited in: Pathophysiology
  20. [20]

    Roztoczyńska D, Roztoczyńska A, Starzyk J. “Bone mineral density and bone turnover in adolescent girls with anorexia nervosa: a 3-year retrospective cohort study.” Frontiers in endocrinology (2026). PMID: 42199795 ↗

    L2COHORTCited in: Pathophysiology
  21. [21]

    Cheng N, Zhao J, Feng C et al.. “The impact of garlic and its active metabolites on degenerative musculoskeletal diseases.” Frontiers in pharmacology (2026). PMID: 42358358 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology
  22. [22]

    Pai KK, Shetye S, Patil R et al.. “Interplay of Mitochondrial Dynamics, Nutrition, and Vitamins: Evidence From Experimental and Human Studies With Implications for Women's Health.” Oxidative medicine and cellular longevity (2026). PMID: 42358203 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology
  23. [23]

    Wang X, Liu J, You H et al.. “Mitochondrial Transport in Bone Metabolism Homeostasis: Molecular Mechanisms and Targeted Therapeutic Strategies.” International journal of molecular sciences (2026). PMID: 42352917 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology
  24. [24]

    Zhang J, Dai Q, Chen Q et al.. “The Important Role of Polycystin in the Skeletal System.” Calcified tissue international (2026). PMID: 42350686 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology
  25. [25]

    Xi Y, Qu Y, Zhang Z et al.. “Apoptotic bodies in bone homeostasis and skeletal disease: biology and therapeutic implications.” Apoptosis : an international journal on programmed cell death (2026). PMID: 42321445 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology
  26. [26]

    Ghazi M, Kherrab A, Chergaoui I et al.. “Moroccan national guidelines for the management of postmenopausal osteoporosis.” Archives of osteoporosis (2026). PMID: 42081156 ↗

    L1GUIDELINECited in: Clinical Presentation and Fracture Risk Assessment, Special Populations (Glucocorticoid-Induced, Male, Postmenopausal, Pediatric), Guidelines and Resources
  27. [27]

    Kanis JA, McCloskey EV, Johansson H et al.. “Predictive value of BMD for hip and other fractures: a meta-analysis to update FRAX.” Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2026). PMID: 41820630 ↗

    L1SR_OBSCited in: Clinical Presentation and Fracture Risk Assessment
  28. [28]

    Yen YH, Wei JC, Ko FS et al.. “Microvascular complications and risk of osteoporosis and fractures in type 2 diabetes: a nationwide Asian cohort study.” Journal of endocrinological investigation (2026). PMID: 42002671 ↗

    L2COHORTCited in: Clinical Presentation and Fracture Risk Assessment
  29. [29]

    Karia CT, Champion T, Dawes L et al.. “Hand fragility fractures as a missed opportunity for secondary prevention: A retrospective cohort study and assessment of the Second Metacarpal Cortical Index.” Injury (2026). PMID: 41966792 ↗

    L3COHORTCited in: Clinical Presentation and Fracture Risk Assessment
  30. [30]

    Ye C, Leslie WD, Al-Azazi S et al.. “A Population-Based Cohort Study of Fracture Risk Among 122,255 Adults Before and After Cancer Diagnosis Compared with Matched Controls.” Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research (2026). PMID: 41804783 ↗

    L3COHORTCited in: Clinical Presentation and Fracture Risk Assessment
  31. [31]

    Jayasuriya AC, Skie M. “Use of artificial intelligence and radiomics for diagnosis and prediction of osteoporotic fractures: a systematic review.” Clinical radiology (2026). PMID: 41955646 ↗

    L2SR_OBSCited in: Clinical Presentation and Fracture Risk Assessment
  32. [32]

    Soong C, Chou YC, Lin KP et al.. “Integrating Machine Learning into Fracture Liaison Services: Toward precision risk stratification in osteoporosis care: A prospective cohort study.” Journal of the Formosan Medical Association = Taiwan yi zhi (2026). PMID: 41945062 ↗

    L2COHORTCited in: Clinical Presentation and Fracture Risk Assessment
  33. [33]

    Issakulova A, Mukhamediyarov M. “Clinical presentation and rehabilitation approaches in patients with ankylosing spondylitis and comorbidities: a multicenter retrospective study.” Rheumatology international (2026). PMID: 41936667 ↗

    L4COHORTCited in: Clinical Presentation and Fracture Risk Assessment
  34. [34]

    Shivam K, Allen J, Aljabrain F et al.. “Management of Bone Health in Breast Cancer Survivors.” JCO oncology practice (2026). PMID: 42269121 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation and Fracture Risk Assessment
  35. [35]

    Shao Y, Yang X, Shi Q et al.. “Osteoporosis in rheumatoid arthritis: a new perspective on risk factors and clinical prediction models.” Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2026). PMID: 42049891 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation and Fracture Risk Assessment
  36. [36]

    Zhou X, Yang N, Xi C et al.. “A network meta-analysis of the effects of different aerobic exercise prescriptions on bone density in osteoporosis patients.” Frontiers in endocrinology (2026). PMID: 42318219 ↗

    L1SR_OBSCited in: Diagnosis and Bone Mineral Density Measurement, Non-Pharmacologic Management (Lifestyle, Nutrition, Fall Prevention)
  37. [37]

    Shin JW, Park MS, Kwon JW et al.. “3D-Printed Porous Titanium versus Polyetheretherketone Cages in Lumbar Interbody Fusion: A Prospective, Multicenter, Randomized Controlled Trial with Bone Mineral Density Stratification.” The spine journal : official journal of the North American Spine Society (2026). PMID: 42349721 ↗

    L1RCTCited in: Diagnosis and Bone Mineral Density Measurement, Monitoring and Treatment Duration, Prognosis and Outcomes
  38. [38]

    Storm NE, Kubik C, Priem G et al.. “Case Study on the Use of Real-World Evidence in a Feasibility Assessment of a Randomized Controlled Trial Design to Support the Fulfillment of Pediatric Requirements with the FDA and EMA.” Therapeutic innovation & regulatory science (2026). PMID: 42319705 ↗

    L5RCTCited in: Diagnosis and Bone Mineral Density Measurement
  39. [39]

    Chandran M, Wong CMJ, Helgason B et al.. “Revisiting the Osteoporosis Self-Assessment Tool (OST): evidence from a multi-cohort study in Asia supporting age-dependent thresholds.” Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2026). PMID: 42360325 ↗

    L2COHORTCited in: Diagnosis and Bone Mineral Density Measurement
  40. [40]

    Afolabi-Brown K, Polavarapu H, Wang JE et al.. “Cervical Disc Replacement Does Not Increase Revision or Reoperation Risk Compared With Fusion in Osteoporotic Women: A Retrospective Matched Cohort Study.” Global spine journal (2026). PMID: 42333545 ↗

    L3COHORTCited in: Diagnosis and Bone Mineral Density Measurement
  41. [41]

    Tseng TH, Huang TT, Huang JE et al.. “AI-derived bone mineral density from standard radiographs compared with DXA for fracture prediction in a 10-year real-world cohort study.” Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2026). PMID: 42313179 ↗

    L2COHORTCited in: Diagnosis and Bone Mineral Density Measurement, Monitoring and Treatment Duration, Prognosis and Outcomes
  42. [42]

    Diz-Lopes M, Rovetta CF, Pollastri F et al.. “Romosozumab does not improve volumetric bone mineral density at distal radius but is associated with early changes in bone strength: a prospective study.” Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2026). PMID: 42313178 ↗

    L2COHORTCited in: Diagnosis and Bone Mineral Density Measurement
  43. [43]

    Zha D, Yao X, Xu M et al.. “Percutaneous pedicle screw combined with percutaneous kyphoplasty for osteoporotic vertebral compression fractures with endplate depression: A randomized controlled trial.” The Journal of international medical research (2026). PMID: 42334329 ↗

    L2RCTCited in: Diagnosis and Bone Mineral Density Measurement
  44. [44]

    Guldan M, Ozbek L, Fidan DG et al.. “Circulating α-Klotho and Multidimensional Aging and Frailty Outcomes: A Systematic Review and Meta-Analysis from the European Renal Association CKD-MBD Working Group.” Calcified tissue international (2026). PMID: 42060134 ↗

    L1SR_OBSCited in: Differential Diagnosis and Evaluation for Secondary Causes, Non-Pharmacologic Management (Lifestyle, Nutrition, Fall Prevention)
  45. [45]

    Kim H, Yao X, Li O et al.. “Bisphosphonate treatment for secondary osteoporosis in children, youth, and young adults: a systematic review and meta-analysis.” Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2026). PMID: 41591403 ↗

    L1SR_OBSCited in: Differential Diagnosis and Evaluation for Secondary Causes
  46. [46]

    Hosseinzadeh N, Mitchell RJ, Wijekulasuriya S et al.. “Systematic Review of Secondary Prevention Interventions and Approaches for Osteoporosis Management in Older People With Hip Fracture.” Australasian journal on ageing (2026). PMID: 41653468 ↗

    L2SR_OBSCited in: Differential Diagnosis and Evaluation for Secondary Causes
  47. [47]

    Soyer AK, Köroğlu EY, Karaahmetli G et al.. “Low forearm bone density as a clue to suspect primary hyperparathyroidism in postmenopausal women with osteoporosis: a retrospective study.” Archives of osteoporosis (2026). PMID: 41656435 ↗

    L3COHORTCited in: Differential Diagnosis and Evaluation for Secondary Causes
  48. [48]

    Loison M, Wargny M, Caillard C et al.. “Radius Bone Mineral Density Measurement Is Essential During Initial PHPT Workup: Results of a Retrospective Study on 400 Patients.” World journal of surgery (2026). PMID: 41486083 ↗

    L3COHORTCited in: Differential Diagnosis and Evaluation for Secondary Causes
  49. [49]

    Balducci S, Haxhi J, Mattia L et al.. “Effects of exercise training on bone health in elderly people with type 2 diabetes without osteoporosis: A randomised clinical trial.” Diabetes research and clinical practice (2026). PMID: 42103115 ↗

    L1RCTCited in: Non-Pharmacologic Management (Lifestyle, Nutrition, Fall Prevention)
  50. [50]

    Massé O, Mercurio CM, Dupuis S et al.. “Calcium, vitamin D, or combined supplementation to prevent fractures and falls: systematic review and meta-analysis.” BMJ (Clinical research ed.) (2026). PMID: 42161415 ↗

    L1SR_OBSCited in: Non-Pharmacologic Management (Lifestyle, Nutrition, Fall Prevention)
  51. [51]

    Suleiman A, Lotfaliany M, Williams LJ et al.. “Key determinants for lowering the risk of joint replacement in weight-bearing joints: a population-based cohort study.” Arthroplasty (London, England) (2026). PMID: 42252460 ↗

    L2COHORTCited in: Non-Pharmacologic Management (Lifestyle, Nutrition, Fall Prevention), Monitoring and Treatment Duration
  52. [52]

    Peng C, Chen B, Chen Z et al.. “Associations of allergic diseases with incident hospital-recorded osteoporosis and major osteoporotic fracture in older adults: a prospective cohort study in the UK Biobank.” BMC geriatrics (2026). PMID: 42249315 ↗

    L2COHORTCited in: Non-Pharmacologic Management (Lifestyle, Nutrition, Fall Prevention)
  53. [53]

    Han CH, Tsai YC, Wang SI et al.. “Denosumab and risk of Type 2 Diabetes Risk Among Patients with Osteoporosis: A Retrospective Cohort Study.” Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (2026). PMID: 42248356 ↗

    L3COHORTCited in: Non-Pharmacologic Management (Lifestyle, Nutrition, Fall Prevention)
  54. [54]

    Ghafarian AM, Wajahath M, McBee K et al.. “One-year mortality after first-time long bone fractures in older adults: A multicenter retrospective cohort study.” Injury (2026). PMID: 42107204 ↗

    L3COHORTCited in: Non-Pharmacologic Management (Lifestyle, Nutrition, Fall Prevention)
  55. [55]

    Yang Z, Luo D, Jiang H et al.. “Association of walking and osteoporosis risk among 432,493 UK participants: A prospective cohort study.” Public health (2026). PMID: 42054719 ↗

    L2COHORTCited in: Non-Pharmacologic Management (Lifestyle, Nutrition, Fall Prevention)
  56. [56]

    Zhou B, Zhang Y, Yu W et al.. “Efficacy and safety of denosumab, zoledronic acid and alendronate on bone mineral density and trabecular bone score in men with osteoporosis.” Age and ageing (2026). PMID: 42096654 ↗

    L1RCTCited in: Pharmacologic Therapy – Antiresorptive Agents, Landmark Trials and Key Evidence
  57. [57]

    Keaveny TM, Oates M, Betah D et al.. “Effects of romosozumab on bone strength around a pedicle screw as evaluated by biomechanical computed tomography-based virtual stress tests in postmenopausal women.” The spine journal : official journal of the North American Spine Society (2025). PMID: 42051047 ↗

    L3RCTCited in: Pharmacologic Therapy – Antiresorptive Agents, Pharmacologic Therapy – Anabolic and Dual-Action Agents
  58. [58]

    Liu L, Ruan X, Gu M et al.. “A randomized controlled trial on the effect of Gushukang on bone mineral density in perimenopausal and postmenopausal women.” Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology (2026). PMID: 42033017 ↗

    L1RCTCited in: Pharmacologic Therapy – Antiresorptive Agents
  59. [59]

    Agarwal N, Bell KR, Ross LE et al.. “The effects of anti-osteoporotic medication on fracture healing and outcomes: a systematic review and meta-analysis.” The lancet. Healthy longevity (2026). PMID: 42229491 ↗

    L1SR_OBSCited in: Pharmacologic Therapy – Antiresorptive Agents
  60. [60]

    Kang G, Qu D, Dong B et al.. “Effects of kaempferol on bone loss in animal models of osteoporosis: a systematic review and meta-analysis.” Frontiers in endocrinology (2026). PMID: 42100197 ↗

    L1SR_OBSCited in: Pharmacologic Therapy – Antiresorptive Agents, Pharmacologic Therapy – Anabolic and Dual-Action Agents
  61. [61]

    Palmowski A, Haugegaard T, Hafström I et al.. “Changes in bone mineral density and fractures during 2 years of low-dose glucocorticoid treatment for rheumatoid arthritis: a systematic literature review and individual participant data meta-analysis.” RMD open (2026). PMID: 42097691 ↗

    L1SR_OBSCited in: Pharmacologic Therapy – Antiresorptive Agents
  62. [62]

    Li Z, Zhang L, Xue C et al.. “Comparative efficacy and safety of antiresorptive and anabolic therapies for male osteoporosis: an updated Bayesian network meta-analysis.” Frontiers in endocrinology (2026). PMID: 41993988 ↗

    L1SR_OBSCited in: Pharmacologic Therapy – Antiresorptive Agents, Pharmacologic Therapy – Anabolic and Dual-Action Agents
  63. [63]

    Bandeira TFGS, Aguiar PM, Vianna CMM et al.. “Romosozumab Versus Teriparatide for the Treatment of Postmenopausal Osteoporosis: An Overview of Systematic Reviews With Direct and Indirect Meta-Analyses.” International journal of rheumatic diseases (2026). PMID: 41999058 ↗

    L2SR_OBSCited in: Pharmacologic Therapy – Antiresorptive Agents
  64. [64]

    Desai A, Khataniar H, Habib H et al.. “Increased osteoporosis burden and comparative antiresorptive effectiveness in inflammatory bowel disease: a real-world cohort study.” Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2026). PMID: 41995805 ↗

    L3COHORTCited in: Pharmacologic Therapy – Antiresorptive Agents
  65. [65]

    Chen L, Wang Q, Gu M. “Assessment of the efficacy and safety of anti-sclerostin antibody therapy for osteoporosis in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials.” Frontiers in endocrinology (2026). PMID: 41635538 ↗

    L1SR_MA_RCTCited in: Pharmacologic Therapy – Anabolic and Dual-Action Agents
  66. [66]

    Tani S, Asada T, Hasegawa H et al.. “Upper arm administration is associated with higher injection site pain with romosozumab: a randomized controlled trial and a self-controlled study.” JBMR plus (2026). PMID: 41798722 ↗

    L1RCTCited in: Pharmacologic Therapy – Anabolic and Dual-Action Agents
  67. [67]

    Leder BZ, Ramchand SK, Jordan M et al.. “3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial.” The lancet. Diabetes & endocrinology (2026). PMID: 41621431 ↗

    L1RCTCited in: Pharmacologic Therapy – Anabolic and Dual-Action Agents
  68. [68]

    Amorim T, David NL, Moturi S et al.. “Effects of teriparatide on hip structure and bone microarchitecture in women with anorexia nervosa: a placebo-controlled randomized trial.” Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2026). PMID: 41591404 ↗

    L1RCTCited in: Pharmacologic Therapy – Anabolic and Dual-Action Agents
  69. [69]

    Deal C, Bostrom MP, Sheth NP et al.. “The effects of abaloparatide on acetabular bone mineral density and proximal femur strength in men with osteoporosis.” Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry (2026). PMID: 41812602 ↗

    L1RCTCited in: Pharmacologic Therapy – Anabolic and Dual-Action Agents
  70. [70]

    Yang Z, Tang R, Ma Y et al.. “The anti-osteoporotic effect of puerarin on the femoral bone in rat models of osteoporosis: a systematic review and meta-analysis.” Frontiers in pharmacology (2026). PMID: 41560734 ↗

    L1SR_OBSCited in: Pharmacologic Therapy – Anabolic and Dual-Action Agents
  71. [71]

    Chai Y, Shi T, Jiang H et al.. “Fibular allograft augmentation shows potential benefits in treating medial column comminuted proximal humeral fractures with osteoporosis: a secondary analysis of a randomized controlled trial.” Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology (2026). PMID: 42350837 ↗

    L3RCTCited in: Monitoring and Treatment Duration, Prognosis and Outcomes
  72. [72]

    Klinger T, Müller K, Graf R et al.. “Duration-Dependent Adverse Events of Systemic Glucocorticosteroids in Atopic Dermatitis: A Nationwide Claims Cohort Study.” Dermatology and therapy (2026). PMID: 42329357 ↗

    L3COHORTCited in: Monitoring and Treatment Duration
  73. [73]

    Pyun J, Hwang M, Yang T et al.. “Erxian decoction for postmenopausal osteoporosis: An updated systematic review and meta-analysis.” Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry (2026). PMID: 42155162 ↗

    L1SR_OBSCited in: Special Populations (Glucocorticoid-Induced, Male, Postmenopausal, Pediatric)
  74. [74]

    Cipolloni V, Bonifacio M, Hassny SM et al.. “The Anabolic-First Strategy in Osteoporosis: A Systematic Review and Meta-Analysis of Fracture Outcomes in Patients at Very High Fracture Risk.” Medicina (Kaunas, Lithuania) (2026). PMID: 42075559 ↗

    L1SR_OBSCited in: Special Populations (Glucocorticoid-Induced, Male, Postmenopausal, Pediatric)
  75. [75]

    Eastell R, Orwoll E, Cosman F et al.. “Efficacy, pharmacodynamics, pharmacokinetics, safety, and immunogenicity of Bmab 1000 vs reference denosumab: 78-wk results from a randomized, double-blind, multicenter, parallel-arm Phase 3 trial (DEVOTE) in women with postmenopausal osteoporosis.” JBMR plus (2026). PMID: 42110973 ↗

    L1TRIAL_NONRANDOMCited in: Special Populations (Glucocorticoid-Induced, Male, Postmenopausal, Pediatric)
  76. [76]

    Wang PC, Su H, Wu LC et al.. “Fragility fractures of the pelvis and long-term outcomes among older adults with osteoporosis: a real-world cohort study.” Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2026). PMID: 42105011 ↗

    L2COHORTCited in: Special Populations (Glucocorticoid-Induced, Male, Postmenopausal, Pediatric)
  77. [77]

    Danzeng Q, Wu F, Cui M et al.. “Macrophage polarization regulates bone homeostasis: a potential etiology and therapy for postmenopausal osteoporosis.” Frontiers in immunology (2026). PMID: 42148148 ↗

    L5REVIEW_NARRATIVECited in: Special Populations (Glucocorticoid-Induced, Male, Postmenopausal, Pediatric)
  78. [78]

    Li X, Hu M, Shen Y. “Synergistic Efficacy of Calcitriol Combined with Denosumab versus Calcitriol Alone in Postmenopausal Osteoporosis: A Retrospective Cohort Study.” International journal of women's health (2026). PMID: 42212302 ↗

    L3COHORTCited in: Special Populations (Glucocorticoid-Induced, Male, Postmenopausal, Pediatric)
  79. [79]

    Nakano R, Ichisawa A, Saruta K et al.. “Prior treatment, not vitamin D, predicts romosozumab response in 314 osteoporosis patients: A retrospective cohort study.” Bone reports (2026). PMID: 42088599 ↗

    L3COHORTCited in: Special Populations (Glucocorticoid-Induced, Male, Postmenopausal, Pediatric)
  80. [80]

    Lindberg PWS, Michelet KM, Alin CK et al.. “The effect of OsteoStrong compared to dynamic multicomponent exercise on bone strength in older women: the BONEMORE non-inferiority randomized controlled trial.” Archives of osteoporosis (2026). PMID: 41748967 ↗

    L1RCTCited in: Landmark Trials and Key Evidence
  81. [81]

    Chen L, Zhao Y, Yang A et al.. “Feasibility and preliminary outcomes of a Rebuilding Osteo Strength with Exercise (ROSE) program for women with breast cancer undergoing endocrine therapy.” European journal of oncology nursing : the official journal of European Oncology Nursing Society (2026). PMID: 41679121 ↗

    L3RCTCited in: Landmark Trials and Key Evidence
  82. [82]

    Wang H, Liu H, Huang J et al.. “Comparative Effects of Minodronate and Alendronate on Low Back Pain in Postmenopausal Osteoporosis and Age Influence: A Head-to-Head, Randomized Clinical Trial.” Clinical interventions in aging (2025). PMID: 41341143 ↗

    L1RCTCited in: Landmark Trials and Key Evidence
  83. [83]

    Schini M, Gossiel F, Paggiosi MA et al.. “Randomized controlled trial of an oral gastrin receptor antagonist for the treatment of postmenopausal osteoporosis.” Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research (2026). PMID: 41206736 ↗

    L1RCTCited in: Landmark Trials and Key Evidence
  84. [84]

    Yang L, Lu F, Chen J et al.. “The effects of Sitting Baduanjin intervention based on the COM-B model for elderly patients with osteoporosis after vertebroplasty: A randomized controlled trial.” Complementary therapies in medicine (2025). PMID: 41167568 ↗

    L1RCTCited in: Landmark Trials and Key Evidence
  85. [85]

    Ramchand SK, Tsai JN, Zhao Y et al.. “Comparative bone histomorphometry effects of combined denosumab and teriparatide vs monotherapy in postmenopausal women with osteoporosis: a randomized controlled trial.” Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research (2026). PMID: 41128757 ↗

    L1RCTCited in: Landmark Trials and Key Evidence
  86. [86]

    Bolland MJ, Nisa Z, Mellar A et al.. “Antifracture Efficacy of 5- or 10-Yearly Zoledronate in Women Aged 50 to 60 Years: Secondary Analyses of a Randomized Trial.” The Journal of clinical endocrinology and metabolism (2026). PMID: 41106822 ↗

    L1RCTCited in: Landmark Trials and Key Evidence
  87. [87]

    Barchetta I, Filardi T, Dule S et al.. “Effect of sitagliptin vs. placebo on bone mineralization in women with type 2 diabetes: the SLowDOWN (SitagLiptin in Diabetes for Osteoporosis in WomeN) randomized clinical trial.” BMC medicine (2025). PMID: 41088165 ↗

    L1RCTCited in: Landmark Trials and Key Evidence
  88. [88]

    Seefried L, Ferrari S, Páll D et al.. “A randomised Phase 3 study comparing the efficacy and safety of proposed denosumab biosimilar RGB-14-P and reference denosumab in women with postmenopausal osteoporosis.” Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2025). PMID: 41085683 ↗

    L1RCTCited in: Landmark Trials and Key Evidence
  89. [89]

    Bassatne A, El Meski N, Horanieh R et al.. “Benefits and harms of antiresorptive therapy in men with non-metastatic prostate cancer on androgen deprivation therapy: A systematic review and meta-analysis of randomized controlled trials.” Metabolism: clinical and experimental (2026). PMID: 42263846 ↗

    L1SR_MA_RCTCited in: Prognosis and Outcomes
  90. [90]

    Esteban-Medina A, de la Oliva V, Fernández Del Valle P et al.. “Menopause age and hypercholesterolemia comorbidities: a region-wide retrospective cohort study in Andalusia, Spain (2016-2022).” BMJ open (2026). PMID: 42264524 ↗

    L3COHORTCited in: Prognosis and Outcomes
  91. [91]

    Feng C, Shu J, Li Y et al.. “The effects of exercise interventions on bone mineral density in middle-aged and older men: a systematic review and meta-analysis.” Frontiers in physiology (2026). PMID: 42291748 ↗

    L1SR_OBSCited in: Prognosis and Outcomes
  92. [92]

    Sidbury R, Alikhan A, Bercovitch L et al.. “Guidelines of care for the primary prevention of atopic dermatitis and awareness of comorbid conditions in pediatric atopic dermatitis.” Journal of the American Academy of Dermatology (2026). PMID: 41949509 ↗

    L1GUIDELINECited in: Guidelines and Resources
  93. [93]

    Panay N, Fenton A, Hamoda H et al.. “International Menopause Society (IMS) recommendations and key messages on women's midlife health and menopause.” Climacteric : the journal of the International Menopause Society (2025). PMID: 41433054 ↗

    L1GUIDELINECited in: Guidelines and Resources
  94. [94]

    Ceccato F, Terzolo M, Gatto F et al.. “Who and how to screen for Cushing's syndrome: the position statement of the Italian Society of Endocrinology.” Journal of endocrinological investigation (2025). PMID: 41364328 ↗

    L1GUIDELINECited in: Guidelines and Resources
  95. [95]

    Carbonell-Abella C, Micó-Pérez RM, Vargas Negrín F et al.. “[SEIOMM-SEMERGEN-semFYC-SEMG recommendations for the management of patients with osteoporosis/fragility fracture in primary care].” Atencion primaria (2026). PMID: 41785613 ↗

    L1GUIDELINECited in: Guidelines and Resources

Revision History

All updates applied to this page

Loading revisions…